Xenitra Completes $1.25M Placement for OTC Medicines and Blockchain Expansion
Xenitra receives $1.25 million in commitments to accelerate OTC medicines expansion and OPAL ecosystem growth
Xenitra has received commitments from institutional, professional and sophisticated investors to raise $1.25 million to fund expansion of its OTC medicines portfolio and blockchain-based OPAL ecosystem. The capital raise supports dual growth pathways across traditional pharmaceutical distribution and digital asset infrastructure.
The placement comprises up to 416,666,667 fully paid ordinary shares issued at $0.003 per share. Investors will receive one unquoted option for every two placement shares, exercisable at $0.004 and expiring 2 April 2028, subject to shareholder approval.
Novus Capital Limited acted as sole lead manager to the placement and will receive a 6% management and selling fee. Novus is also entitled to 30,000,000 options and 15,000,000 shares, subject to shareholder approval. The placement shares will be issued under the company’s existing Listing Rule 7.1 capacity, avoiding delays associated with convening a shareholder meeting.
The option exercise price of $0.004 represents a 33% premium to the placement price. If exercised, the options could provide additional capital and a potential valuation catalyst for the company.
When big ASX news breaks, our subscribers know first
Where the funds will be deployed
Xenitra has outlined four key uses for the proceeds:
- Acceleration of OTC medicines expansion
- Scaling of the OPAL RWA token ecosystem across new brands
- Working capital and infrastructure to support operational growth
- Costs of the placement
The capital allocation targets two distinct revenue pathways. The OTC medicines expansion builds on the company’s existing Formulasia healthcare brand, while the OPAL ecosystem represents a blockchain-based approach to asset tokenisation. This dual focus positions Xenitra across both traditional pharmaceutical distribution and emerging digital infrastructure sectors.
What is an RWA token ecosystem?
Real World Asset (RWA) tokenisation involves creating digital representations of physical or traditional assets on blockchain infrastructure. These tokens allow fractional ownership, improved liquidity and transparent tracking of asset provenance. For Xenitra, the OPAL ecosystem is being scaled across new brands using this technology.
RWA tokenisation is an emerging sector that bridges traditional assets with blockchain infrastructure. By developing the OPAL ecosystem, Xenitra is positioning itself within this growth theme while maintaining its established healthcare product distribution operations.
Placement structure and lead manager arrangements
The placement shares will be issued using the company’s existing Listing Rule 7.1 capacity. This approach allows faster capital deployment without requiring shareholder approval for the placement shares themselves. However, the attaching options and lead manager entitlements do require shareholder approval at a future meeting.
| Item | Detail |
|---|---|
| Placement amount | $1.25 million |
| Shares issued | Up to 416,666,667 |
| Issue price | $0.003 |
| Attaching options | 1 for every 2 shares |
| Option exercise price | $0.004 |
| Option expiry | 2 April 2028 |
Using existing placement capacity allows Xenitra to access capital immediately and begin deploying funds across its stated priorities without waiting for shareholder meeting logistics.
The next major ASX story will hit our subscribers first
Strategic outlook for Xenitra
The $1.25 million raise provides runway to execute on the next phase of growth across both the Formulasia healthcare brand and OPAL digital asset infrastructure. The dual focus on OTC medicines and blockchain tokenisation positions the company across traditional and emerging sectors.
Capital deployment will target acceleration of the OTC medicines business alongside scaling of the OPAL RWA token ecosystem. This approach suggests a diversified growth strategy that balances established pharmaceutical distribution with participation in blockchain-based asset infrastructure.
The placement price of $0.003 and attached options exercisable at $0.004 indicate investor appetite at current levels. If the options are exercised before the 2 April 2028 expiry, the company would receive additional capital and potentially establish a new valuation benchmark.
Want the Next Consumer Discretionary Breakout in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they break.